Navigation Links
Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition
Date:9/12/2008

Paper Reports Value of Specific Nutritional Products is Dependent on

Individual's Genetic Make-up

WALTHAM, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Researchers at Interleukin Genetics, Inc. (Amex: ILI), today received the 12th John M. Kinney Award for Nutrition and Metabolism at the annual Congress of the European Society of Parenteral and Enteral Nutrition, in Florence, Italy. The award was given for the paper, "Interleukin-1 genotype-selective inhibition of inflammatory mediators by a botanical: a nutrigenetics proof of concept," which was published in Nutrition: The International Journal of Applied and Basic Nutritional Sciences (2007;23:844-852).

Kenneth Kornman, Ph.D., Chief Scientific Officer at Interleukin Genetics, and the first author on the publication, commented, "We are honored to receive the 12th John M. Kinney Award for Nutrition and Metabolism. Many botanical and nutritional supplements claim to provide countless health benefits without being subjected to rigorous clinical study. Our paper reports a well- controlled clinical study has shown the value of specific nutritional products is dependent on an individual's genetic make-up."

The study, a joint research effort by scientists at Interleukin Genetics and Nutrilite, a division of Alticor Inc., is one of the few controlled clinical trials that has shown the value of specific nutritional products is dependent on an individual's genetic make-up. The data showed that a proprietary botanical supplement (Nutrilite IL1 Heart Health Supplement) could lower inflammation in individuals who tested positive for pro-inflammatory IL- 1 gene variations from Interleukin Genetics' Heart Health Genetic Test. These individuals also had elevated levels of C-reactive protein.

About Interleukin Genetics' Heart Health Genetic Test

Interleukin Genetics' Heart Health Genetic Test was developed to identify healthy individuals who are genetically predisposed to over-produce inflammation and are at an increased risk for an early first heart attack. The Heart Health Genetic Test is marketed on a non-exclusive basis through Access Business Group International LLC, a division of Alticor Inc. Interleukin Genetics recently announced an agreement with Access Business Group International that will permit the expansion of Interleukin Genetics' distribution network for such genetic tests.

About Nutrilite IL1 Heart Health Supplement

Nutrilite IL1 Heart Health Supplement, a proprietary botanical supplement, was developed to reduce inflammation in those individuals who are genetic over-producers. The Nutrilite IL1 Heart Health Supplement is currently marketed by Quixtar, Inc., a division of Alticor Inc.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Genetics Determine Optimal Drug Dose of Common Anticoagulant
9. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
10. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
11. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is ... many communities have begun providing weekend displays, and numerous households celebrate the unofficial end ... can be downright terrifying for pets. , Kris Zambo, owner of Dynamite ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides ... and safety. By learning and implementing best practices for containment using ventilated safety ... attendees will gain a better understanding of a method for safely testing nanotechnology ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area medical group ... academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one ... and Reconstructive Surgery. The candidate will have the opportunity to work with ...
(Date:8/21/2017)... ... August 21, 2017 , ... SportsEngine, Inc. , a ... Technology Partner of North Country Region Volleyball and will power registration, scheduling, and ... with providing sport management software to their member clubs. , SportsEngine ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... place all over the country. , Outdoor running increases exposure to ultraviolet radiation, ... an increased risk of melanoma, and only half may be adequately protecting themselves ...
Breaking Medicine News(10 mins):